DexCom launches Stelo, first over-the-counter glucose biosensor in U.S., available without prescription
DexCom, a maker of real-time continuous glucose monitoring devices, announced today the availability of Stelo, the first over-the-counter glucose biosensor in the U.S., now purchasable without a prescription at Stelo.com. This new offering is targeted at the 125 million Americans with Type 2 diabetes and those with prediabetes.
Stelo utilizes DexCom's accurate glucose sensing technology to provide personalized insights on how lifestyle factors such as food, exercise, and sleep can impact glucose levels, all delivered directly to a smartphone without the need for painful fingersticks.
Dexcom G7 continuous glucose monitoring system now connects directly to Apple Watch
DexCom has announced that its Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects directly to Apple Watch in the United States. The Dexcom G7 is the first and only CGM system offering real-time glucose readings on the Apple Watch, providing users with freedom and convenience even when their iPhone isn’t with them.
Jake Leach, executive vice president and chief operating officer at Dexcom, stated, “At Dexcom, our users are at the heart of everything we do. Direct to Apple Watch has been one of our most requested features, and we’re thrilled to roll it out to Dexcom G7 users in the U.S. and around the world. We’ve long believed that people with diabetes should be able to view their CGM data where and how they choose. Direct to Apple Watch is a testament to that, allowing people with diabetes flexibility and choice in how they manage their health.”